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Background
A twelve year old female with generalised joint hypermo-
bility (Beighton 8/9) from Noonan's syndrome presented
with chronic neck pain which caused frequent headaches.
Touching the trapezeii reproduced the pain and range of
movement at the cervical spine was decreased. She had
been managed unsuccessfully with manual techniques,
mobilisation, stretches and TENS over the prior twelve
months. Poor sleep due to pain caused fatigue and
decreased participation in school and physical activity.
Materials and methods
N of 1 trial design to investigate the efficacy of Botox® to
reduce muscle spasm.
Baseline measures of weekly average pain (VAS), maxi-
mum pain (VAS), episodes of neck pain, episodes of head-
ache and doses of paracetamol (acetaminophen) were
obtained over 5 weeks. The intervention consisted of
injecting 25 units of Botox® into each trapezius (total 50
units) over multiple sites. Outcome measures were
recorded for seven weeks following treatment. Data was
analysed using the c-statistic method in Excel®.
Results
At six weeks average pain score decreased from a median
of 48.5 to 20.0 (c-statistic p = 0.012). Maximum pain
decreased from a median of 72.0 to 40.0 (c-statistic p =
0.009). Episodes of neck pain per week reduced from a
median of 4 to 2 (c-statistic p = 0.009). No significant
change was seen in the number of episodes of headaches
per week, which reduced from 2 to 1 (p = 0.057). Analge-
sic requirement reduced from 4 paracetamol per week to
2 (c-statistic p = 0.012).
Conclusion
Botulinum toxin injections were an effective treatment.
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